PEPFAR Partnership for Pediatric AIDS Treatment

Partnership objectives

  1. Transition from an emergency response to promotion of sustainable country programs.
  2. Strengthen partner government capacity to lead the response to this epidemic and other health demands.
  3. Expand prevention, care, and treatment in both concentrated and generalized epidemics.
  4. Integrate and coordinate HIV/AIDS programs with broader global health and development programs to maximize impact on health systems.
  5. Invest in innovation and operations research to evaluate impact, improve service delivery and maximize outcomes.

The global HIV/AIDS epidemic requires a comprehensive, multi-sectoral approach that expands access to prevention, care and treatment. Here, Mahalapye resource center, Botswana. The global HIV/AIDS epidemic requires a comprehensive, multi-sectoral approach that expands access to prevention, care and treatment. Here, Mahalapye resource center, Botswana. Copyright MSD

What are the health needs and challenges?

Millions of people in the developing world suffer from HIV/AIDS do not have access to adequate treatment.  As a result, these regions carry very heavy proportions of the global morbidity and mortality burden.

Description of partnership activities and how they address needs and challenges

The US President's Emergency Plan for AIDS Relief (PEPFAR) Partnership for Pediatric AIDS Treatment was launched in 2006. This public-private partnership includes research-based and generic pharmaceutical companies and multilateral organizations such as UNAIDS, WHO and UNICEF. The initiative will identify scientific obstacles to treatment for children, take practical steps to address key barriers, share best practices and develop systems for clinical and technical support.

PEPFAR’s program strategy emphasizes improving health outcomes, increasing program sustainability and integration, and strengthening health systems.

In addition to making medicines available at preferential prices to PEPFAR, Abbott is working with PEPFAR to advance treatment for children with HIV in developing countries by actively participating in the PEPFAR Partnership for Pediatric AIDS Treatment. Abbott also is engaged in helping to advance Early Infant Diagnosis (EID) for detecting HIV in infants in resource limited settings. Additional initiatives include efforts to facilitate registration harmonization, such as between countries in Africa and the Caribbean.

Bristol-Myers Squibb is an active partner in the PEPFAR Partnership for Pediatric AIDS Treatment, working to find solutions to issues concerning pediatric HIV treatment, formulations and access. In 2004, Bristol-Myers Squibb agreed to allow the FDA to make right of reference to its confidential dossiers and product registration files to facilitate approval of generic combination products under the PEPFAR program.

ViiV Healthcare is a supplier of ARVs to PEPFAR at access prices and has also participated in the State Department's program to expand the number of pediatric formulations for HIV medicines that are appropriate for PEPFAR and other child access programs in the developing world.

Bristol-Myers Squibb is an active partner in the PEPFAR Partnership for Pediatric AIDS Treatment, working to find solutions to issues concerning pediatric HIV treatment, formulations and access. In 2004, Bristol-Myers Squibb agreed to allow the FDA to make right of reference to its confidential dossiers and product registration files to facilitate approval of generic combination products under the PEPFAR program.

MSD* works in partnership with the PEPFAR Partnership for Pediatric AIDS Treatment to identify scientific and technical solutions to improve access to antiretroviral treatment for children living with HIV in resource-limited settings.

Lessons learned

The global HIV/AIDS epidemic requires a comprehensive, multi-sectoral approach that expands access to prevention, care and treatment. As PEPFAR works to build upon its successes, it will focus on transitioning from an emergency response to promoting sustainable country programs.

Sustainable programs must be country-owned and country-driven. Given that the AIDS epidemic represents a shared global burden among nations, the next phase of PEPFAR represents an opportunity for the United States to support shared responsibility with partner countries. To seize this opportunity, PEPFAR is supporting countries in taking leadership of the responses to their epidemics. In addition, to support an expanded collective impact at the country level, PEPFAR is increasing collaboration with multilateral organizations.

Sustainable programs must address HIV/AIDS within a broader health and development context. PEPFAR must be responsive to the overall health needs faced by people living with HIV/AIDS (PLWHA), their families, and their communities, linking the HIV response to a diverse array of global health challenges. As a component of the Global Health Initiative, PEPFAR will be carefully and purposefully integrated with other health and development programs.

Integration expands country capacity to address a broader array of health demands and to respond to new and emerging challenges presented by HIV. Strategic coordination furthers the reach of bilateral assistance, leverages the work of multilateral organizations, promotes country ownership, and increases the sustainability of national health programs.

Sustainable programs must build upon strengths and increase efficiencies. PEPFAR is renewing its emphasis on a "whole of government" response, ensuring that agencies focus on core competencies and better coordination to maximize the effectiveness of U.S. Government (USG) assistance. It is also identifying and implementing efficiencies in its work at both field and headquarters levels to ensure value for money. To build upon the strengths of proven programs, PEPFAR is scaling up effective interventions, particularly in prevention. Finally, it is working to ensure that increased access to coverage is accompanied by an emphasis on quality of services.

Summary of impact and forward looking information

As of September 30, 2014, PEPFAR is supporting life-saving antiretroviral treatment for 7.7 million men, women, and children (of which, 4.5 million are receiving direct support and an additional 3.2 million are benefiting from essential technical support to partner countries) and provided care and support for more than 5 million orphans and vulnerable children.

PEPFAR also directly supported HIV counseling and testing for more than 56.7 million people in fiscal year 2014, providing a critical entry point to prevention, treatment, and care.

PEPFAR is currently supporting training for more than 140,000 new health care workers in PEPFAR-supported countries to deliver HIV and other health services.

*MSD is known as Merck & Co. in the USA and Canada.

Videos

Twin boys in Vietnam supported by PEPFAR

Partnership information

Company(ies) Bristol-Myers Squibb , GlaxoSmithKline , MSD , Pfizer

Partner(s) Abbott, UNAIDS, UNICEF, US President´s Emergency Plan for AIDS Relief (PEPFAR), ViiV Healthcare, World Health Organization (WHO)

Type of Partner(s) Government, IGOs, Other Business

Therapeutic Focus Infectious Diseases, Women and Children's Health

Disease(s) Children's Health, HIV/AIDS

Program Type(s) Availability of Treatment - Differential Pricing, Research & Development - Development of Treatments, Research & Development - Pediatric R&D

Targeted Population(s) Children, Mothers, Youth

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, South Asia, Sub-Saharan Africa

Number of Countries 30

Country(ies) Angola, Botswana, Cambodia, China, Côte d'Ivoire, Democratic Republic of the Congo, Dominican Republic, Ethiopia, Ghana, Guyana, Haiti, India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Russia, Rwanda, South Africa, Sudan, Swaziland, Tanzania, Thailand, Uganda, Ukraine, Vietnam, Zambia, Zimbabwe

Start Date 2006

More information PEPFAR website

Anticipated completion date Ongoing